FilingReader Intelligence
Hubei Biocause Pharmaceutical faces second delisting warning
July 21, 2025 at 10:39 AM UTC•By FilingReader AI
Hubei Biocause Pharmaceutical received a second delisting risk warning after failing to disclose its 2024 annual report and 2025 first-quarter report within statutory deadlines.
The company faces potential delisting if it doesn't file the 2024 annual report, verified by over half its directors, within two months. China's securities regulator launched an investigation in May over the delayed filings.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:000627•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Hubei Biocause Pharmaceutical publishes news
Free account required • Unsubscribe anytime